The global apheresis market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.26% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 3.1 Billion |
Market Forecast in 2033
|
USD 5.6 Billion |
Market Growth Rate 2025-2033 | 6.26% |
Apheresis is a procedure of separating donated blood components, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma, to treat various diseases. It assists in treating sickle cell disease wherein red blood cells (RBCs) are shaped abnormally and cannot carry oxygen through the body. It is also employed to remove abnormal white blood cells (WBCs) that thicken the blood and interfere with organ function. In addition, as it aids in treating blood cancers and blood disorders, such as myasthenia gravis and thrombotic thrombocytopenic purpura (TTP), apheresis is widely used in blood collection centers, hospitals, and ambulatory centers across the globe.
The growing demand for apheresis to treat various diseases, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, represents one of the key factors driving the market. Besides this, there is a rise in the utilization of apheresis to collect plasma for treating burnt and trauma patients across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, increasing investments by key market players in research and development (R&D) activities to introduce an enhanced blood purification device that treats severe forms of arteriosclerosis obliterans is positively influencing the market. In addition, the rising demand for source plasma to treat primary immunodeficiency and hemophilia is offering lucrative growth opportunities to industry investors. Apart from this, the growing employment of apheresis as a therapy for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure, is offering a positive market outlook. Additionally, the increasing awareness among the masses about the benefits of apheresis is bolstering the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global apheresis market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on component, product, technology, procedure, application and end user.
Breakup by Component:
Breakup by Product:
Breakup by Technology:
Breakup by Procedure:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation).
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Component, Product, Technology, Procedure, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation) |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global apheresis market was valued at USD 3.1 Billion in 2024.
We expect the global apheresis market to exhibit a CAGR of 6.26% during 2025-2033.
The growing utilization of apheresis in blood collection centers, hospitals, ambulatory centers, etc., as it assists in treating blood disorders, such as myasthenia gravis and Thrombotic Thrombocytopenic Purpura (TTP), is primarily driving the global apheresis market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective surgeries for sickle cell disease, autoimmune hemolytic anemia, cardiac neonatal lupus, etc., to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals, thereby negatively impacting the global market for apheresis.
Based on the component, the global apheresis market has been bifurcated into plasma (plasmapheresis), platelets (plateletpheresis), leukocytes (leukapheresis or leukopheresis), lymphocytes (lymphopheresis or lymphapheresis), and RBC's (erythropheresis). Among these, plasma (plasmapheresis) currently accounts for the largest market share.
Based on the product, the global apheresis market can be segmented into devices, disposables and reagents, and software. Currently, disposables and reagents hold the majority of the total market share.
Based on the technology, the global apheresis market has been divided into centrifugation, membrane separation, and selective adsorption. Among these, centrifugation currently exhibits a clear dominance in the market.
Based on the procedure, the global apheresis market can be categorized into donor/automated apheresis and therapeutic apheresis. Currently, donor/automated apheresis accounts for the majority of the global market share.
Based on the application, the global apheresis market has been segregated into renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and others, where hematological disorders currently hold the largest market share.
Based on the end user, the global apheresis market can be bifurcated into blood centers, hospitals, and others. Currently, blood centers exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global apheresis market include Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited), and Terumo Bct Inc. (Terumo Corporation).